D. Kornbrust

发表

Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes

Ottrina S. Bond, N. Dejneka, S. Wan, 2008, Molecular vision.

Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits.

D. Kornbrust, A. Alberts, J. MacDonald, 1989, The Journal of pharmacology and experimental therapeutics.

Effect of di(2-ethylhexyl) phthalate on DNA repair and lipid peroxidation in rat hepatocytes and on metabolic cooperation in Chinese hamster V-79 cells.

D. Kornbrust, J. Shelburne, P. Ingram, 1984, Journal of toxicology and environmental health.

Variations on the standard protocol design of the hepatocyte DNA repair assay

D. Kornbrust, T. Barfknecht, R. Naismith, 1987, Cell Biology and Toxicology.

Comparison of rat and hamster hepatocyte primary culture/DNA repair assays.

D. Kornbrust, T. Barfknecht, 1984, Environmental mutagenesis.

Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit.

A. Zutshi, A. Levin, D. Kornbrust, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Relative susceptibility of microsomes from lung, heart, liver, kidney, brain and testes to lipid peroxidation: Correlation with vitamin E content

R. Mavis, D. Kornbrust, 1980, Lipids.

Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection.

D. Kornbrust, Elisabeth C R Solano, Amber Beaudry, 2014, Nucleic acid therapeutics.

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.

D. Kornbrust, S. Henry, C. Auletta, 1997, Toxicology.

Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors.

D. Kornbrust, A. Alberts, R. J. Gerson, 1989, The American journal of medicine.

Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics.

Gareth J Waldron, D. Kornbrust, K. Cannon, 2014, Nucleic acid therapeutics.

The role of glutathione and cytochrome P-450 in the metabolism of methyl chloride.

D. Kornbrust, J. Bus, 1983, Toxicology and applied pharmacology.

Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide.

A. Levin, D. Kornbrust, S. Henry, 2002, International immunopharmacology.

Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications

D. Kornbrust, Cindy Farman, 2003, Toxicologic pathology.

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice.

A. Levin, D. Kornbrust, S. Henry, 1997, Antisense & nucleic acid drug development.

Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey.

D. Kornbrust, K. Blanchard, L. Bellon, 2000, Antisense & nucleic acid drug development.

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA

Mark E. Davis, J. Heidel, D. Kornbrust, 2007, Proceedings of the National Academy of Sciences.

Thiobenzamide-induced hepatotoxicity: effects of substituents and route of administration on the nature and extent of liver injury.

D. Kornbrust, J. Deluca, S. Grossman, 1991, Toxicology and applied pharmacology.

Pharmacokinetic properties of several novel oligonucleotide analogs in mice.

R. Griffey, M. Manoharan, S. Crooke, 1996, The Journal of pharmacology and experimental therapeutics.

Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration.

B. Molitoris, E. Feinstein, D. Kornbrust, 2012, Nucleic acid therapeutics.

Metabolism of methyl chloride to formate in rats.

D. Kornbrust, J. Bus, 1982, Toxicology and applied pharmacology.

Microsomal lipid peroxidation. II. Stimulation by carbon tetrachloride.

R. Mavis, D. Kornbrust, Douglas J. Kornbrust, 1980, Molecular pharmacology.

Preclinical evaluation of lovastatin.

S. Prahalada, D. Kornbrust, A. Alberts, 1988, The American journal of cardiology.

Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid

S. Crooke, D. Kornbrust, C. Bennett, 1996 .

Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeutics.

D. Kornbrust, S. Henry, J. Cavagnaro, 2014, Nucleic acid therapeutics.

Effect of silica and volcanic ash on the content of lung alveolar and tissue phospholipids.

D. Kornbrust, G. Hatch, 1984, Environmental research.

Glutathione depletion by methyl chloride and association with lipid peroxidation in mice and rats.

D. Kornbrust, J. Bus, 1984, Toxicology and applied pharmacology.

Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats.

D. Kornbrust, S. Henry, R. Bruner, 1997, Toxicology.

Oligo safety working group exaggerated pharmacology subcommittee consensus document.

A. Guimond, A. Levin, D. Kornbrust, 2013, Nucleic acid therapeutics.

Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.

D. Kornbrust, M. Webb, M. Cremese, 2001, Antisense & nucleic acid drug development.

Testing of 24 food, drug, cosmetic, and fabric dyes in the in vitro and the in vivo/in vitro rat hepatocyte primary culture/DNA repair assays.

D. Kornbrust, T. Barfknecht, 1985, Environmental mutagenesis.

The effect of paraquat on microsomal lipid peroxidation in vitro and in vivo.

R. Mavis, D. Kornbrust, 1980, Toxicology and applied pharmacology.

Effects of 1,1-dichloro-2,2-bis[p-chlorophenyl]ethylene (DDE) on lactation in rats.

D. Kornbrust, B. Schwetz, T. Goehl, 1986, Journal of toxicology and environmental health.

ON LACTATION IN RATS

D. Kornbrust, B. Schwetz, T. Goehl, 2013 .

Microsomal lipid peroxidation. I. Characterization of the role of iron and NADPH.

R. Mavis, D. Kornbrust, Douglas J. Kornbrust, 1980, Molecular pharmacology.

Effects of pretreatment with inducers of hepatic mixed function oxidases on DNA repair elicited by various compounds in hepatocytes from adult and neonatal rats

D. Kornbrust, D. Dietz, 1987, Cell Biology and Toxicology.

An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice.

K. Stecker, D. Kornbrust, S. Cooper, 1997, The Journal of pharmacology and experimental therapeutics.

First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

R. Hickerson, S. Leachman, D. Kornbrust, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys.

D. Kornbrust, P. Cossum, T. Wallace, 1996, The Journal of pharmacology and experimental therapeutics.

Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys.

D. Kornbrust, P. Cossum, T. Wallace, 1996, The Journal of pharmacology and experimental therapeutics.

Effects of pretreatment with pyrazole and inducers of mixed function oxidases on DNA repair elicited by dimethylnitrosamine in rat hepatocytes in vivo and in vitro.

D. Kornbrust, D. Dietz, 1985, Chemico-biological interactions.

Extrapolation of Oligonucleotide Dose Levels Used in Nonclinical Toxicity Studies to Selection of Safe Starting Dose Levels in Human Clinical Trials.

D. Kornbrust, 2019, Nucleic acid therapeutics.

Assessing unintended hybridization-induced biological effects of oligonucleotides

J. Burchard, S. Bartz, M. Lindow, 2012, Nature Biotechnology.

Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.

Jennifer L Marlowe, Violetta Akopian, Priya Karmali, 2017, Nucleic acid therapeutics.

Overview of the Nonclinical Development Strategies and Class-Effects of Oligonucleotide-Based Therapeutics

D. Kornbrust, S. Henry, M. Templin, 2013 .

Association of inhaled [14C]methyl chloride with macromolecules from various rat tissues.

J. Swenberg, D. Kornbrust, J. Bus, 1982, Toxicology and applied pharmacology.

Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.

M. Pangburn, A. Levin, D. Kornbrust, 1997, The Journal of pharmacology and experimental therapeutics.

Chapter 28 – Overview of the Nonclinical Development Strategies and Class-Effects of Oligonucleotide-Based Therapeutics

D. Kornbrust, S. Henry, M. Templin, 2017 .

Aroclor 1254 pretreatment effects on DNA repair in rat hepatocytes elicited by in vivo or in vitro exposure to various chemicals.

D. Kornbrust, D. Dietz, 1985, Environmental mutagenesis.

Inhibition of coagulation by a phosphorothioate oligonucleotide.

W. Novotny, D. Kornbrust, S. Henry, 1997, Antisense & nucleic acid drug development.

Investigations of the Potential for Five β-Lactam Antibiotics to Elicit Type II Hypersensitivity Reactions in Rats and Monkeys

D. Kornbrust, G. Garratty, R. Eydelloth, 1989 .

Comparison of 7 azo dyes and their azo reduction products in the rat and hamster hepatocyte primary culture/DNA-repair assays.

D. Kornbrust, T. Barfknecht, 1984, Mutation research.

Subchronic toxicity studies with the leukotriene D4 antagonist RG 12525.

J. E. Sanders, D. Kornbrust, Z. Jayyosi, 1995, Fundamental and Applied Toxicology.

EFFECTS OF INTRAVENOUS INFUSION OF PHOSPHOROTHIOATE OLIGONUCLEOTIDES ON COAGULATION, COMPLEMENT ACTIVATION AND HEMODYNAMICS

A. Levin, D. Kornbrust, S. Henry, 1997 .

Considerations for the Characterization and Interpretation of Results Related to Alternative Complement Activation in Monkeys Associated with Oligonucleotide-Based Therapeutics.

D. Kornbrust, S. Henry, J. Cavagnaro, 2016, Nucleic Acid Therapeutics.

First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

R. Hickerson, S. Leachman, D. Kornbrust, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Inaugural Article: Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA

Mark E. Davis, J. Heidel, D. Kornbrust, 2007 .

Exaggerated Pharmacology

A. Guimond, D. Kornbrust, Doug Kornbrust, 2018, Oligonucleotide-Based Drugs and Therapeutics.